Cytokine-Mediated Autoimmune Inflammation in the Central Nervous System

The central nervous system (CNS) is typically protected by specialised barriers and immune surveillance mechanisms. In autoimmune conditions such as multiple sclerosis, autoreactive T cells breach these barriers and release cytokines—small proteins that orchestrate immune communication—within the CNS. A complex interplay among T helper subsets (notably Th1 and Th17 cells), myeloid cells and resident glia creates an inflammatory milieu that leads to demyelination, neuronal injury and loss of neurological function. Key cytokines include granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-12 (IL-12) and interleukin-1β (IL-1β), which drive effector cell recruitment, activation and tissue damage. Conversely, certain cytokine signals can trigger protective programmes in neurons and oligodendrocytes, attenuating early degeneration. The balance between pathogenic and neuroprotective cytokine pathways shapes lesion development, repair capacity and clinical outcome. Recent advances reveal how cellular circuits, receptor expression and environmental factors converge to regulate cytokine-mediated inflammation in the CNS, offering new avenues for targeted intervention.

Research from Nature Portfolio

Recent studies have demonstrated that IL-12 receptor signalling in neuroectoderm-derived cells, particularly neurons, induces a tissue adaptation that mitigates early neurodegeneration and sustains trophic factor production during autoimmune challenge. Complementary research comparing genetically identical individuals with and without clinical disease has uncovered an inflammatory shift in peripheral monocytes and an expansion of IL-2-responsive helper T cells bearing CNS-homing receptors; these cells exhibit dysregulated CD25–IL-2 signalling whose proliferative capacity correlates with disease severity. Foundational work has also defined a chemokine receptor switch in developing Th17 cells—from CCR6 to CCR2 usage—driving pathogenic GM-CSF/IFNγ-producing phenotypes and guiding their recruitment into inflamed CNS tissue. Together, these findings illuminate both cell-intrinsic and systemic determinants of cytokine-driven neuroinflammation and point to receptor-based targets for modulating T-cell trafficking and function.

Cytokine-Mediated Autoimmune Inflammation in the Central Nervous System publication trend

The graph below shows the total number of articles in cytokine-mediated autoimmune inflammation in the central nervous system across all publications each year (not limited to Nature Index journals).

Technical terms

Cytokine: Small secreted proteins that mediate and regulate immune responses and inflammation.

Th17 cells: Subset of CD4+ helper T cells characterised by production of interleukin-17 and implicated in driving tissue inflammation.

GM-CSF: Granulocyte-macrophage colony-stimulating factor, a cytokine that promotes differentiation and activation of myeloid cells and amplifies inflammatory cascades.

Interleukin-12: A heterodimeric cytokine that influences T‐cell differentiation and can exert both proinflammatory and neuroprotective effects in the CNS.

Mononuclear phagocyte system: Network of macrophages, monocytes and dendritic cells that maintains tissue homeostasis and mediates antigen presentation and immune responses.

References

1. IL-12 sensing in neurons induces neuroprotective CNS tissue adaptation and attenuates neuroinflammation in mice. Nature Neuroscience (2023).
2. Twin study reveals non-heritable immune perturbations in multiple sclerosis. Nature (2022).
3. CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells. Nature Communications (2015).
4. Mononuclear phagocytes in autoimmune neuroinflammation. Trends in Immunology (2024).
5. Respiratory tract Moraxella catarrhalis and Klebsiella pneumoniae can promote pathogenicity of myelin-reactive Th17 cells. Mucosal Immunology (2023).